Atopic dermatitis: the role of care products in common dermatosis in pediatric practice

封面

如何引用文章

全文:

详细

Background. Atopic dermatitis (AD) is one of the most common skin disorders in pediatric practice. In AD, the barrier function of the skin and moisturizing factors are impaired, which requires using specialized care products. Therefore, healthcare professionals should be aware of effective and safe products that can be used in children.

Aim. To evaluate the clinical efficacy of LA-KRY cosmetics.

Materials and methods. The study included 39 patients with AD and 26 patients with allergic/contact dermatitis aged 0-7 years. In some children, skin corneometric indices (SCI) (humidity and oiliness) were measured before using care products and 14 and 30 days after the start of their use to assess their effectiveness. In the remaining patients, the clinical manifestations of skin disorders were assessed visually without instrumental methods.

Results. SCI improvement was observed after 14 days of using LA-KRY products and significantly improved by the end of month 1. Minimization of dryness and itching of the skin occurred by days 3-5, and clinical manifestations resolved by days 14-30 (depending on the nosology).

Conclusion. LA-KRY have shown their effectiveness in children with several dermatoses associated with skin barrier disruption, dryness, and itching; in particular, they help reduce inflammation and discomfort and normalize SCI.

全文:

受限制的访问

作者简介

Luiza Sakaniya

Center for Theoretical Problems of Physico-Chemical Pharmacology of the Russian Academy of Sciences

Email: marykor@bk.ru
ORCID iD: 0000-0003-2027-5987

Cand. Sci. (Med.)

俄罗斯联邦, Moscow

Olga Smolkina

Center for Theoretical Problems of Physico-Chemical Pharmacology of the Russian Academy of Sciences; LLC “Scientific and Clinical Consulting Center of Allergology and Immunology”

Email: marykor@bk.ru
ORCID iD: 0000-0002-3235-6461

Res. Assist., dermatovenerologist

俄罗斯联邦, Moscow; Moscow

Irina Korsunskaya

Center for Theoretical Problems of Physico-Chemical Pharmacology of the Russian Academy of Sciences

编辑信件的主要联系方式.
Email: marykor@bk.ru
ORCID iD: 0000-0002-6583-0318

Sci. (Med.), Prof.

俄罗斯联邦, Moscow

Natalia Geppe

Sechenov First Moscow State Medical University (Sechenov University)

Email: marykor@bk.ru
ORCID iD: 0000-0003-0547-3686

Sci. (Med.), Prof.

俄罗斯联邦, Moscow

Victoria Soboleva

Sechenov First Moscow State Medical University (Sechenov University); Mechnikov Research Institute of Vaccines and Sera

Email: marykor@bk.ru
ORCID iD: 0000-0003-1758-5909

Cand. Sci. (Med.)

俄罗斯联邦, Moscow; Moscow

参考

  1. Silverberg JI, Simpson EL. Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization. Pediatr Allergy Immunol. 2013;24(5):476-86. doi: 10.1111/pai.12095
  2. Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(Suppl. 1):8-16. doi: 10.1159/000370220
  3. Yang EJ, Sekhon S, Sanchez IM, et al. Recent Developments in Atopic Dermatitis. Pediatrics. 2018;142(4). doi: 10.1542/peds.2018-1102
  4. Kay J, Gawkrodger DJ, Mortimer MJ, Jaron AG. The prevalence of childhood atopic eczema in a general population. J Am Acad Dermatol. 1994;30(1):35-9. doi: 10.1016/s0190-9622(94)70004-4
  5. Thamm R, Poethko-Müller C, Hüther A, Thamm M. Allergische Erkrankungen bei Kindern und Jugendlichen in Deutschland – Querschnittergebnisse aus KiGGS Welle 2 und Trends. J Health Monit. 2018;3:3-18 (in German)]. doi: 10.17886/RKI-GBE-2018-075
  6. Siegels D, Haufe E, Heinrich L, et al. Status report on the atopic dermatitis registry TREATgermany. Allergol Select. 2021;5:274-86. doi: 10.5414/ALX02262E
  7. Flohr C, Mann J. New insights into the epidemiology of childhood atopic dermatitis. Allergy. 2014;69(1):3-16. doi: 10.1111/all.12270
  8. Kage P, Zarnowski J, Simon JC, Treudler R. Atopic dermatitis and psychosocial comorbidities - What’s new? Allergol Select. 2020;4:86-96. doi: 10.5414/ALX02174E
  9. Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338-51. doi: 10.1016/j.jaad.2013.10.010
  10. Yew YW, Thyssen JP, Silverberg JI. A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics. J Am Acad Dermatol. 2019;80(2):390-401. doi: 10.1016/j.jaad.2018.09.035
  11. Wollenberg A, Werfel T, Ring J, et al. Atopic Dermatitis in Children and Adults – Diagnosis and Treatment. Dtsch Arztebl Int. 2023;120(13):224-34. doi: 10.3238/arztebl.m2023.0011
  12. Lodén M, Andersson AC, Anderson C, et al. A double-blind study comparing the effect of glycerin and urea on dry, eczematous skin in atopic patients. Acta Derm Venereol. 2002;82(1):45-7. doi: 10.1080/000155502753600885
  13. van Zuuren EJ, Fedorowicz Z, Christensen R, et al. Emollients and moisturisers for eczema. Cochrane Database Syst Rev. 2017;2(2):CD012119. doi: 10.1002/14651858.CD012119.pub2
  14. Simpson EL, Chalmers JR, Hanifin JM, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol. 2014;134(4):818-23. doi: 10.1016/j.jaci.2014.08.005
  15. Horimukai K, Morita K, Narita M, et al. Application of moisturizer to neonates prevents development of atopic dermatitis. J Allergy Clin Immunol. 2014;134(4):824-30.e6. doi: 10.1016/j.jaci.2014.07.060
  16. Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema - part II: non-systemic treatments and treatment recommendations for special AE patient populations. J Eur Acad Dermatol Venereol. 2022;36(11):1904-26. doi: 10.1111/jdv.18429
  17. van Zuuren EJ, Fedorowicz Z, Christensen R, et al. Emollients and moisturisers for eczema. Cochrane Database Syst Rev. 2017;2(2):CD012119. doi: 10.1002/14651858.CD012119.pub2
  18. Kawashima M, Hayashi N, Nogita T, et al. The usefulness of moisturizers for maintenance of remission in atopic dermatitis. Jpn J Dermatol. 2007;117:1139-45.
  19. El-Saber Batiha G, Magdy Beshbishy A, El-Mleeh A, et al. Traditional Uses, Bioactive Chemical Constituents, and Pharmacological and Toxicological Activities of Glycyrrhiza glabra L. (Fabaceae). Biomolecules. 2020;10(3). doi: 10.3390/biom10030352
  20. Mostafa ES, Maher A, Mostafa DA, et al. A Unique Acylated Flavonol Glycoside from Prunus persica (L.) var. Florida Prince: A New Solid Lipid Nanoparticle Cosmeceutical Formulation for Skincare. Antioxidants (Basel). 2021;10(3). doi: 10.3390/antiox10030436
  21. Danby SG, Andrew PV, Taylor RN, et al. Different types of emollient cream exhibit diverse physiological effects on the skin barrier in adults with atopic dermatitis. Clin Exp Dermatol. 2022;47(6):1154-64. doi: 10.1111/ced.15141
  22. Zhao G, He F, Wu C, et al. Betaine in Inflammation: Mechanistic Aspects and Applications. Front Immunol. 2018;9:1070. doi: 10.3389/fimmu.2018.01070
  23. Ebner F, Heller A, Rippke F, Tausch I. Topical use of dexpanthenol in skin disorders. Am J Clin Dermatol. 2002;3(6):427-33. doi: 10.2165/00128071-200203060-00005

补充文件

附件文件
动作
1. JATS XML
下载
2. Fig. 1. Symptoms of atopic dermatitis (AD) before starting therapy.

下载 (68KB)
索引源数据
3. Fig. 2. AD symptoms after 30 days of therapy.

下载 (61KB)
索引源数据
4. Fig. 3. Symptoms of allergic dermatitis (AlD) before treatment.

下载 (71KB)
索引源数据
5. Fig. 4. AlD symptoms after 14 days of therapy

下载 (70KB)
索引源数据
6. Fig. 5. Symptoms persistence during the use of LA-KRY therapeutic cosmetics.

下载 (85KB)
索引源数据

版权所有 © Consilium Medicum, 2024

Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74329 от 19.11.2018 г.


##common.cookie##